In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.
AUTOR(ES)
Gooding, B B
RESUMO
CP-99,219 is a trifluoronaphthyridone with significant antibacterial activity that includes the family Enterobacteriaceae (MICs for 90% of the strains tested [MIC90s], < or = 0.015 to 0.5 micrograms/ml), Moraxella catarrhalis, Haemophilus influenzae, and gonococci (MICs, < or = 0.015 micrograms/ml). Legionella spp. were also CP-99,219 susceptible, with MICs of 0.008 to 0.12 micrograms/ml. CP-99,219 demonstrated activity greater than that of ciprofloxacin, ofloxacin, or enoxacin against Pseudomonas aeruginosa (MIC90, 1 microgram/ml), Xanthomonas maltophilia (MIC90, 2 micrograms/ml), Staphylococcus haemolyticus (MIC90, 0.5 micrograms/ml), Enterococcus faecalis (MIC90, 1 microgram/ml), and pneumococci (MIC90, 0.12 micrograms/ml). Numerous ciprofloxacin-resistant isolates were susceptible to CP-99,219, a new compound showing potential value for further in vivo trials.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=187667Documentos Relacionados
- In Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
- In vitro activity of a new fluoroquinolone, CP-99,219, against strains of Neisseria gonorrhoeae.
- In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.
- In vitro activity of the new fluoroquinolone CP-99,219.
- Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.
